GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Benzylpenicilloyl polylysine | GSK-239512 may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with GSK-239512. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-239512. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with GSK-239512. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with GSK-239512. |
| Amphetamine | Amphetamine may decrease the sedative activities of GSK-239512. |
| Phentermine | Phentermine may decrease the sedative activities of GSK-239512. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of GSK-239512. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of GSK-239512. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of GSK-239512. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of GSK-239512. |
| Mephentermine | Mephentermine may decrease the sedative activities of GSK-239512. |
| MMDA | MMDA may decrease the sedative activities of GSK-239512. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of GSK-239512. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of GSK-239512. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of GSK-239512. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of GSK-239512. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of GSK-239512. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of GSK-239512. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of GSK-239512. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of GSK-239512. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of GSK-239512. |
| Ritobegron | Ritobegron may decrease the sedative activities of GSK-239512. |
| Mephedrone | Mephedrone may decrease the sedative activities of GSK-239512. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of GSK-239512. |
| Gepefrine | Gepefrine may decrease the sedative activities of GSK-239512. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of GSK-239512. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of GSK-239512. |
| Hyoscyamine | GSK-239512 may increase the anticholinergic activities of Hyoscyamine. |